| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/19/2006 | EP1646391A1 Use of 2h-[1,3]-oxazino[3,2-a]indole derivatives for the treatment of neuropathic pain |
| 04/19/2006 | EP1646390A1 A1 adenosine receptor antagonists |
| 04/19/2006 | EP1646389A1 Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| 04/19/2006 | EP1646388A2 Cytotoxic indeno and isoindoloisoquinolones |
| 04/19/2006 | EP1646387A1 Use of indazole derivatives for the treatment of neuropathic pain |
| 04/19/2006 | EP1646386A2 Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor |
| 04/19/2006 | EP1646385A2 Use of benzothiopenes to treat and prevent prostate cancer |
| 04/19/2006 | EP1646384A1 Enema preparation |
| 04/19/2006 | EP1646383A1 Design and synthesis of optimized ligands for ppar |
| 04/19/2006 | EP1646382A2 Compounds, compositions and methods |
| 04/19/2006 | EP1646381A2 Combination therapy for treating chronic inflammatory diseases |
| 04/19/2006 | EP1646380A2 Indolocarbazole anticancer agents and methods of using same |
| 04/19/2006 | EP1646379A2 Novel solid pharmaceutical composition comprising amisulpride |
| 04/19/2006 | EP1646378A1 Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences |
| 04/19/2006 | EP1646377A2 Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator |
| 04/19/2006 | EP1646376A1 Use of cis-9, trans-11 isomer of conjugated linoleic acid (cla) for treating inflammatory diseases |
| 04/19/2006 | EP1646375A2 Treatment of protein aggregation disorders |
| 04/19/2006 | EP1646374A1 Extended-release tablets of metformin |
| 04/19/2006 | EP1646373A2 Orodispersible pharmaceutical composition of an antithrombotic compound |
| 04/19/2006 | EP1646372A2 Methods of diagnosis and treatment for asthma based on haplotype association |
| 04/19/2006 | EP1646371A2 Antiviral compounds and methods |
| 04/19/2006 | EP1646369A2 Saquinavir mesylate oral dosage form |
| 04/19/2006 | EP1646368A1 Dual drug dosage forms with improved separation of drugs |
| 04/19/2006 | EP1646365A1 Powdery formulations for inhalation, containing a novel anticholinergic agent |
| 04/19/2006 | EP1646364A1 Hfc solution formulations containing an anticholinergic |
| 04/19/2006 | EP1646353A2 Fusion proteins for the treatment of cns |
| 04/19/2006 | EP1646328A2 Treatment of dependence withdrawal |
| 04/19/2006 | EP1646292A2 Isomaltulose or trehalose containing comestibles for sustained carbohydrate energy release and increased fat oxidation |
| 04/19/2006 | EP1646284A2 Azole derivatives and methods for making the same |
| 04/19/2006 | EP1646282A1 Genetic vaccines for cancer therapy |
| 04/19/2006 | EP1585483A4 Topical stabilized prostaglandin e compound dosage forms |
| 04/19/2006 | EP1572708B1 Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof |
| 04/19/2006 | EP1572339A4 Biodegradable polyurethane/urea compositions |
| 04/19/2006 | EP1572198B1 New pharmaceutical compounds with alpha2receptor activity |
| 04/19/2006 | EP1562573B1 Pharmaceutical pellets comprising tamsulosin and a process for making the same |
| 04/19/2006 | EP1556371B1 Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor |
| 04/19/2006 | EP1556140A4 Novel compounds |
| 04/19/2006 | EP1545562B1 Branched alpha-glucans for weight management |
| 04/19/2006 | EP1537112B1 Condensed pyridines and pyrimidines with tie2 (tek) activity |
| 04/19/2006 | EP1534711B1 Phenyl-substituted pyrazolopyrimidines |
| 04/19/2006 | EP1521523A4 Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues |
| 04/19/2006 | EP1513833B1 Novel 3-(4-oxo-4h-chromen-2-yl)-(1h)-quinoline-4-one derivatives, method for preparing same and pharmaceutical compositions containing same |
| 04/19/2006 | EP1492569A4 Aqueous dispersible steryl ester compositions |
| 04/19/2006 | EP1487801B1 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo¬d|azepine derivatives with 5-ht6 receptor affinity for the treatment of cns disorders |
| 04/19/2006 | EP1481002B1 Histogranin-like peptides and non-peptides, processes for their preparation and uses thereof |
| 04/19/2006 | EP1474122A4 Compounds for blocking androgen receptors |
| 04/19/2006 | EP1472236A4 Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide |
| 04/19/2006 | EP1471924B1 Idraparinux (sanorg 34006) for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis |
| 04/19/2006 | EP1463730B1 Pyrazolopyridazine derivatives |
| 04/19/2006 | EP1458418B1 Disinfection agent for suction systems used in the field of medicine |
| 04/19/2006 | EP1448564B1 Substituted indolizine-like compounds and methods of use |
| 04/19/2006 | EP1448184B1 Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie s disease |
| 04/19/2006 | EP1436005A4 Inhibition of neonatal hyperbilirubinemia in breast fed infants |
| 04/19/2006 | EP1423363B1 Oral antidiabetic agents |
| 04/19/2006 | EP1423166B1 Non-peptide ccr1 receptor antagonists for the treatment of progressive renal fibrosis |
| 04/19/2006 | EP1420784B1 Compounds effecting glucokinase |
| 04/19/2006 | EP1409001B1 Mineral-protein preparations (mpp) and neuropathies in diabetes |
| 04/19/2006 | EP1401439B1 Use of bicyclo compounds for treating alzheimer's disease |
| 04/19/2006 | EP1387838B1 Cyanoanthranilamide derivatives and the use thereof as medicaments |
| 04/19/2006 | EP1385577B1 Use of nk-1 receptor antagonists against benign prostatic hyperplasia |
| 04/19/2006 | EP1383736A4 Peptide deformylase inhibitors |
| 04/19/2006 | EP1383729A4 Peptide deformylase inhibitors |
| 04/19/2006 | EP1373396A4 Highly nucleated thermoplastic articles |
| 04/19/2006 | EP1370559B1 Triazolopyridines as anti-inflammatory agents |
| 04/19/2006 | EP1368016B1 Parenteral dosage forms comprising a suspension of tramadol salt and diclofenac salt |
| 04/19/2006 | EP1365777B1 Compositions comprising proteoglycan and their use for the treatment of inflammatory conditions |
| 04/19/2006 | EP1353921B1 Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors |
| 04/19/2006 | EP1349833B1 Indole and dihydroindole derivatives |
| 04/19/2006 | EP1339706B1 N-type calcium channel antagonists for the treatment of pain |
| 04/19/2006 | EP1339695B1 Farnesyltransferase inhibitors |
| 04/19/2006 | EP1339407B1 Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease |
| 04/19/2006 | EP1317428B1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors |
| 04/19/2006 | EP1313458B1 GENE CONFERRING RESISTANCE TO THE ANTIBACTERIAL 4,5-DIHYDROXY-2-CYCLOPENTEN-1-ONE (DHCP), THE PROTEIN ENCODED BY the SAME, AND APPLICATIONS THEREOF |
| 04/19/2006 | EP1299102B1 Use of riluzole or its salts for preventing and treating adrenoleukodystrophy |
| 04/19/2006 | EP1296959B1 Methods and compositions utilizing quinazolinones |
| 04/19/2006 | EP1294724B1 Pyrrolo¬2,3-d|pyrimidine compounds as immunosuppressive agents |
| 04/19/2006 | EP1292290B1 Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase i and ii inhibitors |
| 04/19/2006 | EP1259125B1 Inulin products with improved nutritional properties |
| 04/19/2006 | EP1255537B1 Farnesyl protein transferase inhibitors for treating breast cancer |
| 04/19/2006 | EP1255452B1 A method for maintaining or improving the synthesis of mucins |
| 04/19/2006 | EP1253924B1 Nitrate salts of antimicrobial agents |
| 04/19/2006 | EP1250350B1 Novel crystalline composites comprising phytosterols and phytostanols or derivatives thereof |
| 04/19/2006 | EP1246640B1 Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections |
| 04/19/2006 | EP1240133B1 Methods of preparing substituted tetracyclines with transition metal-based chemistries |
| 04/19/2006 | EP1239857B1 Dual-release compositions of a cyclooxygenase-2- inhibitor |
| 04/19/2006 | EP1239849B1 Pharmaceutical formulations comprising resveratrol and use thereof |
| 04/19/2006 | EP1237886B1 Meglumine salt of a specific quinolinecarboxylic acid compound active on nmda receptors |
| 04/19/2006 | EP1227820B1 Oligosaccharide aldonic acids and their topical use |
| 04/19/2006 | EP1216067B1 Polyhydroxyalkanoate compositions for soft tissue repair, augmentation, and viscosupplementation |
| 04/19/2006 | EP1212330B1 Androgen receptor modulator compounds and methods |
| 04/19/2006 | EP1204650B1 Substituted 2-arylbenzazole compounds and their use as antitumour agents |
| 04/19/2006 | EP1196167B1 Use of p38 MAPK inhibitors in the treatment of ophthalmic conditions |
| 04/19/2006 | EP1189890B1 Dihydrobenzodiazepins and their use for treating dyslipidemia |
| 04/19/2006 | EP1177176B1 Tri-aryl acid derivatives as ppar receptor ligands |
| 04/19/2006 | EP1143940B1 Compositions and methods for mucosal delivery |
| 04/19/2006 | EP1143806B1 Method for increasing pet activity |
| 04/19/2006 | EP1126853B1 Controlled delivery of antidepressants |
| 04/19/2006 | EP1120419B1 Derivatives of isosorbid mononitrate, utilization as vasodilator agents with reduced tolerance |
| 04/19/2006 | EP1112284B1 Piperazine-4-phenyl derivatives as inhibitors of the interaction between mdm2 and p53 |
| 04/19/2006 | EP1107772B1 Composition with bacillus coagulans and use thereof |